AstraZeneca: ovarian cancer drug improves survival rate.
(CercleFinance.com) - According to a phase III trial, an AstraZeneca drug that kills cancer cells increases the survival of patients who have a certain type of ovarian cancer.
AstraZeneca today reported new data from a study on Lynparza tablet maintenance treatment showing that quality of life is sustained alongside improved progression-free survival in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.
The trial showed a "significant" quality-adjusted progression-free survival benefit of 14 months with the molecule, compared to 7.3 months with placebo.
Separately, Sweden's Orexo said that a novel treatment of respiratory disorders, such as asthma, has advanced into clinical phase I triggering a milestone payment of 2.5 million dollars from AstraZeneca.
Finally, AstraZeneca has appointed Professor Nazneen Rahman, the head of the division of genetics and epidemiology at the Institute of cancer Research (ICR) in London, as a non-executive director and member of the science committee.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
AstraZeneca today reported new data from a study on Lynparza tablet maintenance treatment showing that quality of life is sustained alongside improved progression-free survival in women with germline BRCA-mutated (gBRCAm), platinum-sensitive, relapsed serous ovarian cancer.
The trial showed a "significant" quality-adjusted progression-free survival benefit of 14 months with the molecule, compared to 7.3 months with placebo.
Separately, Sweden's Orexo said that a novel treatment of respiratory disorders, such as asthma, has advanced into clinical phase I triggering a milestone payment of 2.5 million dollars from AstraZeneca.
Finally, AstraZeneca has appointed Professor Nazneen Rahman, the head of the division of genetics and epidemiology at the Institute of cancer Research (ICR) in London, as a non-executive director and member of the science committee.
Copyright (c) 2017 CercleFinance.com. All rights reserved.